Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Protalix BioTherapeutics, Inc. (PLX) vs Veraxa Biotech AG (VRXA)

Protalix BioTherapeutics, Inc. and Veraxa Biotech AG are both Biotechnology companies. Protalix BioTherapeutics, Inc. and Veraxa Biotech AG are of similar size ($221.6M and $217.0M).

Valuation

Metric PLX VRXA Biotechnology median
P/E 11.33 — 7.88
P/S 2.70 — 11.47
P/B 3.05 — 2.52
Price to free cash flow 28.37 — 21.16
EV/EBITDA 7.27 — 0.74
EV/Sales 2.24 — 10.73
Earnings yield 8.82% — (28.84%)
Free cash flow yield 3.52% — (23.03%)

Profitability

Metric PLX VRXA Biotechnology median
Gross margin 69.20% — 65.16%
Operating margin 28.89% — 0.00%
Net margin 23.50% — 0.00%
Free cash flow margin 9.51% — 0.00%
Return on equity 31.23% — (57.72%)
Return on assets 20.07% — (49.22%)
Return on invested capital 48.48% — 0.00%

Growth

Metric PLX VRXA Biotechnology median
Revenue growth (TTM) 30.14% — 5.64%
EPS growth (last fiscal year) (300.00%) — —
Revenue growth, 5-year CAGR (3.46%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric PLX VRXA Biotechnology median
Debt to equity 0.00 — 0.00
Current ratio 2.94 — 4.73
Net debt to EBITDA 7.68 — 0.96

Dividend

Metric PLX VRXA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric PLX VRXA Biotechnology median
Market cap 221.57m 217.00m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack